HRP20040250A2 - Crystals of hydroxynorephedrine derivative - Google Patents

Crystals of hydroxynorephedrine derivative Download PDF

Info

Publication number
HRP20040250A2
HRP20040250A2 HR20040250A HRP20040250A HRP20040250A2 HR P20040250 A2 HRP20040250 A2 HR P20040250A2 HR 20040250 A HR20040250 A HR 20040250A HR P20040250 A HRP20040250 A HR P20040250A HR P20040250 A2 HRP20040250 A2 HR P20040250A2
Authority
HR
Croatia
Prior art keywords
compound
pollakiuria
urinary incontinence
ethyl
fact
Prior art date
Application number
HR20040250A
Other languages
English (en)
Croatian (hr)
Inventor
Isawa Hidetoshi
Hotei Yukihiko
Kasai Kiyoshi
Sonehara Junichi
Akahane Satoshi
Harada Hiromu
Original Assignee
Kissei Pharmaceutical Co.Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co.Ltd. filed Critical Kissei Pharmaceutical Co.Ltd.
Publication of HRP20040250A2 publication Critical patent/HRP20040250A2/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HR20040250A 2001-09-13 2004-03-12 Crystals of hydroxynorephedrine derivative HRP20040250A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001277345 2001-09-13
PCT/JP2002/008596 WO2003024916A1 (fr) 2001-09-13 2002-08-27 Cristaux d'un derive d'hydroxynorephedrine

Publications (1)

Publication Number Publication Date
HRP20040250A2 true HRP20040250A2 (en) 2005-02-28

Family

ID=19101883

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040250A HRP20040250A2 (en) 2001-09-13 2004-03-12 Crystals of hydroxynorephedrine derivative

Country Status (29)

Country Link
US (1) US7208520B2 (fr)
EP (1) EP1426355B1 (fr)
JP (1) JP4157036B2 (fr)
KR (2) KR20080098691A (fr)
CN (1) CN1275936C (fr)
AT (1) ATE411276T1 (fr)
AU (1) AU2002330453B2 (fr)
BR (1) BR0212494A (fr)
CA (1) CA2458544C (fr)
CO (1) CO5560555A2 (fr)
CY (1) CY1109409T1 (fr)
DE (1) DE60229404D1 (fr)
DK (1) DK1426355T3 (fr)
EA (1) EA006022B1 (fr)
EC (1) ECSP045017A (fr)
ES (1) ES2314092T3 (fr)
HK (1) HK1070051A1 (fr)
HR (1) HRP20040250A2 (fr)
HU (1) HUP0401694A3 (fr)
IL (2) IL160681A0 (fr)
MX (1) MXPA04002449A (fr)
NO (1) NO328252B1 (fr)
NZ (1) NZ531602A (fr)
PL (1) PL206246B1 (fr)
PT (1) PT1426355E (fr)
SI (1) SI1426355T1 (fr)
UA (1) UA77000C2 (fr)
WO (1) WO2003024916A1 (fr)
ZA (1) ZA200401757B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
ATE401878T1 (de) * 2003-05-05 2008-08-15 Kissei Pharmaceutical Verwendung von phenoxyessigsäurederivaten zur behandlung der hyperaktiven blase
DE10351271A1 (de) * 2003-10-31 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz
EP1682183A2 (fr) * 2003-11-03 2006-07-26 Boehringer Ingelheim International Gmbh Composition pharmaceutique contenant un agoniste des recepteurs beta-3-adrenergiques et un antagoniste alpha et/ou un inhibiteur de la 5-alpha-reductase
DE10352132A1 (de) * 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
WO2005092321A1 (fr) * 2004-03-24 2005-10-06 Kissei Pharmaceutical Co., Ltd. Composition pharmaceutique pour la prevention ou le traitement de la frequence urinaire accrue ou de l’urination involontaire
JP4808613B2 (ja) * 2004-03-24 2011-11-02 キッセイ薬品工業株式会社 頻尿または尿失禁の予防または治療用医薬
DK1612203T3 (da) * 2004-06-28 2007-12-03 Gruenenthal Gmbh Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid
JP2008516909A (ja) * 2004-10-18 2008-05-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 前立腺及び下部泌尿生殖路の病気を治療するためのβ−3アゴニストの使用
DE102004050952A1 (de) * 2004-10-18 2006-04-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung von Beschwerden, die mit krankhaften Veränderungen oder Irritationen der Prostata verbunden sind
JP2008517886A (ja) 2004-10-26 2008-05-29 キッセイ薬品工業株式会社 フェノキシ酢酸誘導体の合成
TWI356699B (en) * 2004-11-10 2012-01-21 Kissei Pharmaceutical Agent for treating interstitial cystitis and agent
JPWO2006118087A1 (ja) * 2005-04-26 2008-12-18 キッセイ薬品工業株式会社 ヒドロキシノルエフェドリン誘導体塩酸塩・1/4水和物の結晶
EP1878719A4 (fr) * 2005-04-26 2010-10-06 Kissei Pharmaceutical Cristal polymorphe de chlorhydrate de derive d'hydroxynorephedrine
EP1769792A1 (fr) 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Utilisation d'un du récepteur béta-3-adrénergique pour le traitement des troubles rénaux et vésicaux
CA2695634C (fr) 2007-08-06 2018-01-23 Serenity Pharmaceuticals Corporation Procedes et dispositifs pour l'administration de medicament desmopressine
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
DK3225250T3 (da) 2008-05-21 2019-11-04 Ferring Bv Orodispersibel desmopressin til forlængelse af den indledende søvnperiode, som ikke forstyrres af nykturi

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY126489A (en) * 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
JP4005730B2 (ja) * 1999-01-21 2007-11-14 キッセイ薬品工業株式会社 アミノエチルフェノキシ酢酸誘導体二水和物の結晶多形
JP4005729B2 (ja) * 1999-01-21 2007-11-14 キッセイ薬品工業株式会社 アミノエチルフェノキシ酢酸誘導体二水和物の結晶多形
JP4005731B2 (ja) * 1999-01-21 2007-11-14 キッセイ薬品工業株式会社 アミノエチルフェノキシ酢酸誘導体の結晶多形

Also Published As

Publication number Publication date
BR0212494A (pt) 2004-08-24
HUP0401694A2 (hu) 2004-11-29
ZA200401757B (en) 2005-03-03
KR20040044881A (ko) 2004-05-31
PL206246B1 (pl) 2010-07-30
CA2458544A1 (fr) 2003-03-27
US7208520B2 (en) 2007-04-24
CA2458544C (fr) 2010-08-17
DK1426355T3 (da) 2009-02-23
NZ531602A (en) 2006-01-27
PT1426355E (pt) 2008-11-03
HUP0401694A3 (en) 2008-03-28
JPWO2003024916A1 (ja) 2004-12-24
NO20041060L (no) 2004-06-11
CN1275936C (zh) 2006-09-20
ECSP045017A (es) 2004-09-27
WO2003024916A1 (fr) 2003-03-27
UA77000C2 (en) 2006-10-16
US20040242686A1 (en) 2004-12-02
CN1553890A (zh) 2004-12-08
EA200400311A1 (ru) 2004-08-26
IL160681A0 (en) 2004-08-31
CO5560555A2 (es) 2005-09-30
KR100874952B1 (ko) 2008-12-19
ES2314092T3 (es) 2009-03-16
MXPA04002449A (es) 2004-07-23
ATE411276T1 (de) 2008-10-15
PL367874A1 (en) 2005-03-07
HK1070051A1 (en) 2005-06-10
CY1109409T1 (el) 2014-07-02
DE60229404D1 (de) 2008-11-27
AU2002330453B2 (en) 2008-04-17
NO328252B1 (no) 2010-01-18
SI1426355T1 (sl) 2009-02-28
IL160681A (en) 2010-06-16
EP1426355A4 (fr) 2006-03-29
EP1426355B1 (fr) 2008-10-15
EP1426355A1 (fr) 2004-06-09
EA006022B1 (ru) 2005-08-25
KR20080098691A (ko) 2008-11-11
JP4157036B2 (ja) 2008-09-24

Similar Documents

Publication Publication Date Title
HRP20040250A2 (en) Crystals of hydroxynorephedrine derivative
US10399920B2 (en) Crystalline form of cannabidiol
CN104379559B (zh) 化合物
EP1991523B1 (fr) Modulateurs sélectifs de récepteur androgène
US9029420B2 (en) Agomelatine and pharmaceutical compositions thereof
JP4054366B2 (ja) 疾患の治療のために有用な化合物
JP2022500395A (ja) ファルネソイドx受容体アゴニストの結晶形態
US7763654B2 (en) Crystal polymorph of hydroxynorephedrin derivative hydrochloride
RU2761213C2 (ru) Соль и полиморф фенил-пиримидонового соединения, их фармацевтическая композиция и применение
TW202120471A (zh) 作為Kv7鉀通道開放劑的醇衍生物
TW201904954A (zh) 一種苯并哌啶類衍生物的鹽、其晶型及鹽、其晶型的製備方法
US8003694B2 (en) Crystal of hydroxynorephedrin derivative hydrochloride ¼ hydrate
TW202412741A (zh) 一種製備2-羥乙基胺基己酸酯類化合物方法及其應用
EP1954260A2 (fr) Derives d'isocysteine pour le traitement de douleur
CN103360276A (zh) 阿戈美拉汀的晶型、制备方法和用途、以及药物组合物

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20110701

Year of fee payment: 10

OBST Application withdrawn